Product Information
Registration Status: ActiveSIN14960P
POLIO SABIN ONE AND THREE (ORAL) VACCINE is approved to be sold in Singapore with effective from 2016-02-23. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN14960P.
This product contains Virus Polio Type 1 Not Applicable,strain LSc ,2ab ,Virus Polio Type 3 ,strain Leon 12a , and 1b in the form of SUSPENSION. It is approved for ORAL use.
This product is manufactured by GSK Biologicals SA in Belgium.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent. [PubChem]
Indication
For use in keratoconjunctivitis and keratitis caused by herpes simplex virus.
Mechanism of Action
Idoxuridine acts as an antiviral agent by inhibiting viral replication by substituting itself for thymidine in viral DNA. This in turn inhibits thymidylate phosphorylase and viral DNA polymerases from properly functioning. The effect of Idoxuridine results in the inability of the virus to reproduce or to infect/destroy tissue.
Pharmacokinetics
- Absorption
- Systemic absorption is unlikely following ocular administration even when nasolacrimal secretions are swallowed, since vidarabine is rapidly deaminated in the gastrointestinal tract.
- Distribution
- Metabolism
- Idoxuridine is rapidly inactivated by deaminases or nucleotidases.
- Elimination
Toxicity
Hypersensitivity or increased sensitivity of eyes to light. LD50=3080 mg/kg (orally in mice).
Active Ingredient/Synonyms
(+)-5-Iodo-2'-deoxyuridine | 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil | 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil | 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil | 2'-Deoxy-5-iodouridine | 5-iodo-2'-deoxyuridine | 5-Iododeoxyuridine | 5-Iodouracil deoxyriboside | Idoxuridin | Idoxuridina | Idoxuridine | Idoxuridinum | IdU | Iododeoxyridine | Iodoxuridine | Joddeoxiuridin | Idoxuridine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.